Arcus Biosciences to Participate in Upcoming Investor Conferences
Arcus Biosciences (NYSE:RCUS) announced upcoming presentations at key virtual investor conferences. Management will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, Cowen's 41st Annual Health Care Conference on March 2, and Barclays Global Healthcare Conference on March 10. Investors can access live audio webcasts on the Arcus website, with replays available for at least two weeks post-event. Arcus focuses on developing innovative cancer therapies, with multiple drug candidates in clinical trials addressing significant unmet needs.
- None.
- None.
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming 2021 virtual investor conferences:
- 10th Annual SVB Leerink Global Healthcare Conference, Friday, February 26 at 12:00 pm ET
- Cowen 41st Annual Health Care Conference, Tuesday, March 2 at 11:10 am ET
- Barclays Global Healthcare Conference, Wednesday, March 10 at 1:15 pm ET
A live audio webcast of each presentation will be available by visiting the “Investors” section of the Arcus website at www.arcusbio.com. A replay of each webcast will be available for at least two weeks following the live event.
About Arcus Biosciences
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. In addition, domvanalimab is advancing into ARC-10, Arcus’s “two in one trial” to support the potential approvals of both zimberelimab and zimberelimab + domvanalimab and a registrational study, in collaboration with AstraZeneca, evaluating the curative-intent stage III NSCLC setting. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005864/en/
FAQ
What are the upcoming conferences where Arcus Biosciences will present in 2021?
How can I access the presentations from Arcus Biosciences?
What is the focus of Arcus Biosciences?
What are some drug candidates developed by Arcus Biosciences?
When will the live webcasts be available for replay?
